Literature DB >> 29196927

Characteristics of cerebellar glioblastomas in adults.

Thiébaud Picart1, Marc Barritault2,3,4, Julien Berthillier5, David Meyronet3,4,6, Alexandre Vasiljevic4,6, Didier Frappaz7, Jérôme Honnorat4,8,9, Emmanuel Jouanneau4,10,11, Delphine Poncet2,4, François Ducray3,4,8, Jacques Guyotat12.   

Abstract

Adult cerebellar glioblastomas (cGBM) are rare and their characteristics remain to be fully described. We analyzed the characteristics of 17 adult patients with cGBM and compared them to a series of 103 patients presenting a supra-tentorial glioblastoma (stGBM). The mean age at GBMc diagnosis was 53.4 years (range 28-77). A history of neurofibromatosis type I was noted in 3 patients. cGBM were hemispheric in 10 patients (58.8%), only vermian in 4 patients (23.5%), and both vermian and hemispheric in 3 patients (17.7%). A H3 K27M mutation was identified in 3/14 patients, a TERT promoter mutation in 3/14 patients and a methylated MGMT promoter in 3/14 patients. None of the patients (0/14) harbored an EGFR amplification, an IDH or a BRAF mutation. Association with neurofibromatosis type I and H3K27M mutations were mutually exclusive. Compared with stGBM, cGBM occurred in younger patients (53.4 vs. 63.2, p = 0.02), were more frequently associated with neurofibromatosis type I (18 vs. 1%, p = 0.009) and with a H3 K27M mutation (21 vs. 3%, p = 0.02). They also tended to have a more frequent multifocal presentation at diagnosis (21 vs. 4.3%, p = 0.06), more frequently resulted in leptomeningeal or intra-axial metastasis (44.5 vs. 5%, p = 0.002) and were associated with a shorter median overall survival (5.9 vs. 14.2 months, p = 0.004). The present study suggests that adult cGBM differ from their supra-tentorial counterpart and constitute a heterogeneous group of IDH wild-type gliomas with at least two subgroups, one associated with H3K27M mutations and the other with neurofibromatosis type I.

Entities:  

Keywords:  Cerebellar glioblastoma; Histone H3.3 K27M; Leptomeningeal dissemination; Multifocal glioblastoma; Neurofibromatosis type I

Mesh:

Year:  2017        PMID: 29196927     DOI: 10.1007/s11060-017-2682-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  50 in total

Review 1.  Primary cerebellar glioblastoma multiforme.

Authors:  S A Levine; P E McKeever; H S Greenberg
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

2.  Primary glioblastoma of the cerebellar vermis: A case report.

Authors:  Xiaolin Jing; Guohua Shen; Minggang Su; Rong Tian; Zhiyun Jia
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

3.  Glioblastoma multiforme in the posterior cranial fossa in a patient with neurofibromatosis type I.

Authors:  Marike L D Broekman; Roelof Risselada; Jooyeon Engelen-Lee; Wim G M Spliet; Bon H Verweij
Journal:  Case Rep Med       Date:  2009-12-16

4.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

Authors:  Dominik Sturm; Hendrik Witt; Volker Hovestadt; Dong-Anh Khuong-Quang; David T W Jones; Carolin Konermann; Elke Pfaff; Martje Tönjes; Martin Sill; Sebastian Bender; Marcel Kool; Marc Zapatka; Natalia Becker; Manuela Zucknick; Thomas Hielscher; Xiao-Yang Liu; Adam M Fontebasso; Marina Ryzhova; Steffen Albrecht; Karine Jacob; Marietta Wolter; Martin Ebinger; Martin U Schuhmann; Timothy van Meter; Michael C Frühwald; Holger Hauch; Arnulf Pekrun; Bernhard Radlwimmer; Tim Niehues; Gregor von Komorowski; Matthias Dürken; Andreas E Kulozik; Jenny Madden; Andrew Donson; Nicholas K Foreman; Rachid Drissi; Maryam Fouladi; Wolfram Scheurlen; Andreas von Deimling; Camelia Monoranu; Wolfgang Roggendorf; Christel Herold-Mende; Andreas Unterberg; Christof M Kramm; Jörg Felsberg; Christian Hartmann; Benedikt Wiestler; Wolfgang Wick; Till Milde; Olaf Witt; Anders M Lindroth; Jeremy Schwartzentruber; Damien Faury; Adam Fleming; Magdalena Zakrzewska; Pawel P Liberski; Krzysztof Zakrzewski; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Sorana Morrissy; Florence Cavalli; Michael D Taylor; Peter van Sluis; Jan Koster; Rogier Versteeg; Richard Volckmann; Tom Mikkelsen; Kenneth Aldape; Guido Reifenberger; V Peter Collins; Jacek Majewski; Andrey Korshunov; Peter Lichter; Christoph Plass; Nada Jabado; Stefan M Pfister
Journal:  Cancer Cell       Date:  2012-10-16       Impact factor: 31.743

5.  Glioblastoma multiforme of the cerebellum in an elderly man.

Authors:  Tomonori Tamaki; Tsuneyoshi Eguchi; Masaki Sakamoto; Akira Teramoto
Journal:  J Chin Med Assoc       Date:  2004-06       Impact factor: 2.743

6.  Molecular analysis of diffuse intrinsic brainstem gliomas in adults.

Authors:  German Reyes-Botero; Marine Giry; Karima Mokhtari; Marianne Labussière; Ahmed Idbaih; Jean-Yves Delattre; Florence Laigle-Donadey; Marc Sanson
Journal:  J Neurooncol       Date:  2013-11-17       Impact factor: 4.130

7.  Characteristics of H3 K27M-mutant gliomas in adults.

Authors:  David Meyronet; Maud Esteban-Mader; Charlotte Bonnet; Marie-Odile Joly; Emmanuelle Uro-Coste; Alexandra Amiel-Benouaich; Fabien Forest; Cécilia Rousselot-Denis; Fanny Burel-Vandenbos; Véronique Bourg; Jacques Guyotat; Tanguy Fenouil; Anne Jouvet; Jérôme Honnorat; François Ducray
Journal:  Neuro Oncol       Date:  2017-08-01       Impact factor: 12.300

8.  O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents.

Authors:  T Walter; B van Brakel; C Vercherat; V Hervieu; J Forestier; J-A Chayvialle; Y Molin; C Lombard-Bohas; M-O Joly; J-Y Scoazec
Journal:  Br J Cancer       Date:  2015-01-13       Impact factor: 7.640

9.  Distinct molecular profile of diffuse cerebellar gliomas.

Authors:  Masashi Nomura; Akitake Mukasa; Genta Nagae; Shogo Yamamoto; Kenji Tatsuno; Hiroki Ueda; Shiro Fukuda; Takayoshi Umeda; Tomonari Suzuki; Ryohei Otani; Keiichi Kobayashi; Takashi Maruyama; Shota Tanaka; Shunsaku Takayanagi; Takahide Nejo; Satoshi Takahashi; Koichi Ichimura; Taishi Nakamura; Yoshihiro Muragaki; Yoshitaka Narita; Motoo Nagane; Keisuke Ueki; Ryo Nishikawa; Junji Shibahara; Hiroyuki Aburatani; Nobuhito Saito
Journal:  Acta Neuropathol       Date:  2017-08-29       Impact factor: 17.088

10.  Long-term tumor control of spinal dissemination of cerebellar glioblastoma multiforme by combined adjuvant bevacizumab antibody therapy: a case report.

Authors:  Thomas Linsenmann; Camelia M Monoranu; Giles H Vince; Thomas Westermaier; Carsten Hagemann; Almuth F Kessler; Ralf-Ingo Ernestus; Mario Löhr
Journal:  BMC Res Notes       Date:  2014-08-07
View more
  11 in total

1.  Treatment patterns and outcomes for cerebellar glioblastoma in the concomitant chemoradiation era: A National Cancer database study.

Authors:  Michael Zhang; Richard Li; Erqi L Pollom; Arya Amini; Savita Dandapani; Gordon Li
Journal:  J Clin Neurosci       Date:  2020-11-06       Impact factor: 1.961

Review 2.  Leptomeningeal Spread in Glioblastoma: Diagnostic and Therapeutic Challenges.

Authors:  Cristina Birzu; Suzanne Tran; Franck Bielle; Mehdi Touat; Karima Mokhtari; Nadia Younan; Dimitri Psimaras; Khe Hoang-Xuan; Marc Sanson; Jean-Yves Delattre; Ahmed Idbaih
Journal:  Oncologist       Date:  2020-08-31

3.  Management, functional outcomes and survival in a French multicentric series of 118 adult patients with cerebellar glioblastoma.

Authors:  Luc Bauchet; Jacques Guyotat; Thiébaud Picart; David Meyronet; Johan Pallud; Chloé Dumot; Philippe Metellus; Sonia Zouaoui; Moncef Berhouma; François Ducray
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-05       Impact factor: 4.553

4.  Diffuse midline glioma with H3-K27M mutation: A rare case with GFAP-positive anucleate whorled patterns.

Authors:  Yi-Hua Wang; Jian Gu; Juan-Han Yu; Lin Fu; Qing-Chang Li; Xue-Shan Qiu; En-Hua Wang
Journal:  Medicine (Baltimore)       Date:  2022-06-17       Impact factor: 1.817

5.  cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".

Authors:  Daniel J Brat; Kenneth Aldape; Howard Colman; Eric C Holland; David N Louis; Robert B Jenkins; B K Kleinschmidt-DeMasters; Arie Perry; Guido Reifenberger; Roger Stupp; Andreas von Deimling; Michael Weller
Journal:  Acta Neuropathol       Date:  2018-09-26       Impact factor: 17.088

6.  Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.

Authors:  Alexandra McAleenan; Claire Kelly; Francesca Spiga; Ashleigh Kernohan; Hung-Yuan Cheng; Sarah Dawson; Lena Schmidt; Tomos Robinson; Sebastian Brandner; Claire L Faulkner; Christopher Wragg; Sarah Jefferies; Amy Howell; Luke Vale; Julian P T Higgins; Kathreena M Kurian
Journal:  Cochrane Database Syst Rev       Date:  2021-03-12

7.  Glioblastoma in a female neurofibromatosis 1 patient without IDH1, BRAF V600E, and TERT promoter mutations: A case report.

Authors:  Jia-Wei Cai; Xiao-Yong Chen; Jin-Yuan Chen; Zan-Yi Wu; Xi-Yue Wu; Liang-Hong Yu; Hong-Hai You
Journal:  Medicine (Baltimore)       Date:  2021-04-02       Impact factor: 1.817

8.  Rapid Brainstem Infiltration of a Cerebellar Glioblastoma.

Authors:  Orlando De Jesus; Juan Vigo; María Oliver-Ricart; Juan L Pérez-Berenguer
Journal:  Cureus       Date:  2022-02-27

9.  TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.

Authors:  Erik A Williams; Julie J Miller; Shilpa S Tummala; Tristan Penson; A John Iafrate; Tareq A Juratli; Daniel P Cahill
Journal:  Acta Neuropathol Commun       Date:  2018-10-17       Impact factor: 7.801

10.  The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis.

Authors:  Huy Gia Vuong; Thu Quynh Nguyen; Tam N M Ngo; Hoang Cong Nguyen; Kar-Ming Fung; Ian F Dunn
Journal:  BMC Cancer       Date:  2020-09-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.